No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
Findings show no significant reduction in primary end point, MACE for those receiving vaccine after acute coronary syndromes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.